Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 20 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 20 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
OXYTOCIN 20 USP UNITS IN DEXTROSE 5% vs SYNTOCINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that acts on oxytocin receptors (OXTR) in uterine myometrium and mammary gland epithelium, leading to Gq/11-coupled phospholipase C activation, increasing intracellular Ca2+ and promoting uterine smooth muscle contractions. It also stimulates milk ejection by contracting myoepithelial cells.
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Initial infusion at 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until desired uterine activity, then taper. Maximum dose typically 20 mU/min.
10 units (1 mL) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 mU/min (0.1-0.5 mL/min) titrated to uterine response.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (IV), with a slower second phase of 12–20 minutes. Clinical context: Rapid clearance necessitates continuous IV infusion for sustained uterotonic effect.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Primarily renal (>99% as intact peptide, small amount as metabolites). Biliary/fecal excretion negligible.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Category C
Category C
Oxytocic
Oxytocic